3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Head & Neck
1
Conditions
Lymphoma
3
Stomatitis
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mucositis
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Small Cell
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
20
Cisplatin
17
Cetuximab
13
Docetaxel
11
Paclitaxel
9
Carboplatin
9
Radiotherapy
8
Fluorouracil
6
cemiplimab
5
130-nm albumin-bound paclitaxel
5
Bleomycin
4
Radiation
3
Pemetrexed
3
Panitumumab
3
Nivolumab
3
Gemcitabine
3
Albumin-Bound Paclitaxel
3
vandetanib
2
talimogene laherparepvec
2
selinexor
2
motexafin gadolinium
2
figitumumab
2
brigatinib
2
avelumab
2
atezolizumab
2
alpha-2'-deoxythioguanosine
2
advexin
2
Taxes
2
ON 01910
2
Methotrexate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Squamous Cell
×
RRx-001
×
Clear all
NCT05966194
2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2
Recruiting
216 enrolled